Combined immune checkpoint inhibitor therapy with nivolumab and ipilimumab causing acute-onset type 1 diabetes mellitus following a single administration: two case reports
- Resource Type
- article
- Authors
- Marco Zezza; Christophe Kosinski; Carine Mekoguem; Laura Marino; Haithem Chtioui; Nelly Pitteloud; Faiza Lamine
- Source
- BMC Endocrine Disorders, Vol 19, Iss 1, Pp 1-5 (2019)
- Subject
- Immune checkpoint inhibitor
Autoimmune adverse events
Endocrinopathies
Type 1 diabetes
Diseases of the endocrine glands. Clinical endocrinology
RC648-665
- Language
- English
- ISSN
- 1472-6823
Abstract Background The use of immune checkpoint inhibitor (ICI) therapy is becoming a standard of care for several cancers. Monoclonal antibodies targeting cytotoxic T-lymphocyte antigen-4 (CTLA-4) and programmed cell death protein 1 (PD-1) or its ligand (PD-L1) cause a broad spectrum of autoimmune adverse events. ICI-induced type 1 diabetes mellitus (T1DM) is extremely rare (